---
title: "Luoxin Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 5.65 million yuan, turning a profit compared to a loss in the same period last year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236832315.md"
description: "According to the Zhitong Finance APP, Luoxin Pharmaceutical disclosed its first-quarter report for 2025, showing that the company achieved revenue of 483 million yuan during the reporting period, a year-on-year decrease of 29.91%; the net profit attributable to the parent company was 5.65 million yuan, turning from a loss to a profit year-on-year; the net profit excluding non-recurring gains and losses was 670,000 yuan, also turning from a loss to a profit year-on-year. The basic earnings per share were 0.01 yuan"
datetime: "2025-04-21T16:41:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236832315.md)
  - [en](https://longbridge.com/en/news/236832315.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236832315.md)
generator: "portal-rs"
---

# Luoxin Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 5.65 million yuan, turning a profit compared to a loss in the same period last year

According to the Zhitong Finance APP, Luoxin Pharmaceutical (002793.SZ) disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 483 million yuan, a year-on-year decrease of 29.91%; the net profit attributable to the parent company was 5.65 million yuan, turning from a loss to a profit year-on-year; the net profit excluding non-recurring gains and losses was 670,000 yuan, also turning from a loss to a profit year-on-year. The basic earnings per share were 0.01 yuan

### Related Stocks

- [002793.CN](https://longbridge.com/en/quote/002793.CN.md)

## Related News & Research

- [My Mountain Mover Recognized Among the 2026 Inc. 5000 Fastest-Growing U.S. Companies](https://longbridge.com/en/news/297087696.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [UPDATE -- Helium Evolution Closes $25 Million Private Placement](https://longbridge.com/en/news/296948264.md)
- [RCS - ZAGENO - ZAGENO and ORO Labs Partnership](https://longbridge.com/en/news/297046609.md)
- [Acea delays shareholder meeting to Sept. 28 from Sept. 7](https://longbridge.com/en/news/296996238.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**